STEMLINE THERAPEUTICS INC's ticker is STML and the CUSIP is 85858C107. A total of 93 filers reported holding STEMLINE THERAPEUTICS INC in Q4 2018. The put-call ratio across all filers is 1.49 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2020 | $4,282,000 | -54.5% | 884,698 | 0.0% | 0.00% | 0.0% |
| Q4 2019 | $9,404,000 | +32.3% | 884,698 | +29.6% | 0.00% | 0.0% |
| Q3 2019 | $7,107,000 | -37.1% | 682,698 | -7.5% | 0.00% | 0.0% |
| Q2 2019 | $11,302,000 | -4.0% | 737,698 | -19.4% | 0.00% | 0.0% |
| Q1 2019 | $11,767,000 | -14.4% | 915,698 | -36.7% | 0.00% | -50.0% |
| Q4 2018 | $13,745,000 | -46.7% | 1,446,798 | -6.9% | 0.00% | -33.3% |
| Q3 2018 | $25,789,000 | -19.4% | 1,553,548 | -22.1% | 0.00% | -25.0% |
| Q2 2018 | $31,988,000 | -33.6% | 1,993,041 | -36.7% | 0.00% | -33.3% |
| Q1 2018 | $48,197,000 | +69.8% | 3,150,159 | +73.1% | 0.01% | +100.0% |
| Q4 2017 | $28,383,000 | +27.7% | 1,819,441 | -9.1% | 0.00% | 0.0% |
| Q3 2017 | $22,222,000 | -4.9% | 2,001,941 | -21.1% | 0.00% | 0.0% |
| Q2 2017 | $23,358,000 | +7.6% | 2,538,892 | 0.0% | 0.00% | 0.0% |
| Q1 2017 | $21,708,000 | +37.5% | 2,538,892 | +72.1% | 0.00% | +50.0% |
| Q4 2016 | $15,787,000 | -21.7% | 1,475,435 | -20.7% | 0.00% | -33.3% |
| Q3 2016 | $20,159,000 | +60.0% | 1,861,392 | 0.0% | 0.00% | +50.0% |
| Q2 2016 | $12,602,000 | +45.2% | 1,861,392 | -0.0% | 0.00% | +100.0% |
| Q1 2016 | $8,677,000 | -30.2% | 1,861,914 | -5.5% | 0.00% | -50.0% |
| Q4 2015 | $12,434,000 | -24.4% | 1,970,601 | +5.8% | 0.00% | 0.0% |
| Q3 2015 | $16,441,000 | -25.0% | 1,861,914 | +0.0% | 0.00% | -33.3% |
| Q2 2015 | $21,909,000 | -23.0% | 1,861,392 | -5.3% | 0.00% | -25.0% |
| Q1 2015 | $28,446,000 | +1.6% | 1,965,892 | +19.8% | 0.00% | 0.0% |
| Q4 2014 | $27,994,000 | +36.9% | 1,640,892 | 0.0% | 0.00% | +33.3% |
| Q3 2014 | $20,446,000 | -15.1% | 1,640,892 | 0.0% | 0.00% | 0.0% |
| Q2 2014 | $24,072,000 | -27.9% | 1,640,892 | 0.0% | 0.00% | -40.0% |
| Q1 2014 | $33,409,000 | +15.5% | 1,640,892 | +11.2% | 0.01% | +25.0% |
| Q4 2013 | $28,929,000 | -58.1% | 1,475,992 | -3.2% | 0.00% | -63.6% |
| Q3 2013 | $69,090,000 | +95.4% | 1,525,492 | +2.9% | 0.01% | +83.3% |
| Q2 2013 | $35,354,000 | – | 1,482,956 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 453,000 | $4,168,000 | 1.58% |
| Eventide Asset Management | 1,086,400 | $9,995,000 | 0.62% |
| SPHERA FUNDS MANAGEMENT LTD. | 300,000 | $2,760,000 | 0.47% |
| Lyon Street Capital, LLC | 125,595 | $1,155,000 | 0.46% |
| CARL DOMINO INC | 26,000 | $239,000 | 0.28% |
| PURA VIDA INVESTMENTS, LLC | 60,000 | $552,000 | 0.22% |
| KNOTT DAVID M | 41,692 | $384,000 | 0.16% |
| SABBY MANAGEMENT, LLC | 187,500 | $1,725,000 | 0.11% |
| FARALLON CAPITAL MANAGEMENT LLC | 1,157,500 | $10,649,000 | 0.11% |
| Telemetry Investments, L.L.C. | 25,000 | $230,000 | 0.11% |